Oliver Sexton joined Midven in April 2014 to manage the UK Innovation & Science Seed Fund’s synthetic biology investments.
Prior to joining Midven, Oliver managed commercialisation of bioengineering and medical technologies At Imperial Innovations and was on the board of oncology therapeutic Acublate Ltd. Earlier in his career he held commercial and partnering roles at Ark Therapeutics. Oliver also managed a team of biotech buy-side analysts and worked at a pharma strategy consultancy.
Oliver has a BSc in Molecular Biology/Biotechnology and an MSc in Plant Science from Bristol University.